New Delhi: Hair restoration has entered a new era—one that goes far beyond cosmetic enhancement and touches the core of mental health, self-esteem, and quality of life. In a recent international study, led by Dr. Michael Gold, founder and medical director, Gold Skin Care Center, USA, and published in the Journal of Cosmetic and Laser Therapy, evidence shows that QR678 Neo is not only a breakthrough in hair regrowth but also a technology with potential applications across medicine.
QR678 Neo, a biomimetic polypeptide hair regrowth formulation developed by Indian cosmetic surgeons Dr. Debraj Shome and Dr. Rinky Kapoor, was granted a US patent in 2017 and subsequently secured both an Indian patent and Indian regulatory approval in 2019.
For Dr. Gold, the shift in how hair loss is perceived is key to understanding the significance of QR678 Neo. “Haircare has transitioned from being viewed purely as an appearance issue to being integral to overall well-being. Today, it’s linked directly with self-confidence and mental health,” he explains. “This evolution has driven the hair restoration market beyond $4 billion and set expectations for solutions that are not just cosmetic, but clinically validated and lasting.”
From patchy solutions to precision science
Earlier therapies such as minoxidil and finasteride offered only modest relief, while surgical options like FUE (Follicular Unit Extraction) and FUT (Follicular Unit Transplantation) raised the bar on outcomes. Adjunctive treatments—PRP and meso-cocktails—added to the mix but often lacked consistency. Against this backdrop, QR678 Neo has emerged as a transformative innovation.
“India has become a hub for meaningful clinical innovation,” says Dr. Gold. “QR678 Neo, patented in both India and the US, exemplifies how intellectual property, rigorous clinical research, and accessibility can intersect to redefine the global standard. In multi-ethnic trials, we saw up to 88% reduction in hair fall and nearly 87% of patients reporting an increase in terminal hair counts. These are numbers that speak to efficacy and safety.”
Specific India study data
The clinical study tested QR678 Neo on 112 Indian men who had not responded to standard hair-loss treatments like minoxidil or finasteride for at least a year. The study was done in two parts: first, participants received injections of QR678 Neo into the scalp; second, during hair transplant procedures, hair grafts were stored in QR678 Neo instead of the usual saline solution.
The results were promising—participants showed noticeable improvements in scalp health, and the transplanted hair had a much higher survival rate when stored in QR678 Neo. These findings highlight that QR678 Neo can be effective not only as a non-surgical hair regrowth treatment but also as an important aid during hair transplant surgeries.
The international study further highlights QR678 Neo’s benefit in hair transplantation. Pre-operatively, it conditions the scalp, strengthening follicles and enhancing vascularity. Intra-operatively, it serves as a graft storage solution—delivering 43% higher graft uptake compared to normal saline. Post-operatively, continued administration accelerates regrowth and improves both density and shaft thickness.
While most treatments stall at male-pattern baldness, QR678 Neo is proving versatile across multiple forms of hair loss. “In alopecia areata, pairing it with corticosteroids enhances outcomes. In chemotherapy-induced alopecia, it rejuvenates follicles damaged by cytotoxic agents—an unmet need in oncology. We are also studying its use in seborrheic dermatitis and COVID-related telogen effluvium,” Dr. Gold notes.
The formulation’s angiogenic, anti-inflammatory, and proliferative properties make it adaptable across conditions. Its minimally invasive administration and consistent results further distinguish it from PRP or minoxidil, which are often plagued by variability and systemic side effects.
Towards a regenerative future
For Dr. Gold, QR678 Neo represents more than just a product. “This is a platform—one that bridges laboratory science with clinical care. By decoding regenerative pathways like Wnt, BMP, Notch, Sonic Hedgehog, and AKT/MAPK, we are reframing alopecia as a regenerative signaling disorder, not an irreversible cosmetic issue.”
“QR678 Neo is not just setting a new bar for hair restoration—it’s redefining the very science of regeneration. This is where the future lies: science-driven, pathway-targeted, and globally scalable,” he concluded.
